ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1560693

This article is part of the Research TopicCommunity Series in Biomarkers in the Era of Cancer Immunotherapy: Zooming in from Periphery to Tumor Microenvironment, Volume IIIView all articles

Expression of PSMD14 in Lung Adenocarcinoma and Its Impact on Immune Cell Infiltration and Prognosis: A Comprehensive Analysis Based on RNA and Single-Cell RNA Sequencing

Provisionally accepted
Jing  ZhangJing Zhang1Bohao  SunBohao Sun1Jiabin  LaiJiabin Lai1Weike  KongWeike Kong1Nan  WangNan Wang2Panyuan  LiPanyuan Li3Yichen  WuYichen Wu1*Zhaochang  JiangZhaochang Jiang1*
  • 1Department of Pathology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
  • 2Department of Pharmacy, Zhejiang Province People’s Hospital, Hangzhou, Jiangsu Province, China
  • 3department of pathology, sir run run shaw, zhejiang university school of medicine,Hangzhou, Hangzhou, China

The final, formatted version of the article will be published soon.

Background: Lung adenocarcinoma is distinguished by intricate relationships between tumor advancement and the immune microenvironment. The function of PSMD14 (Proteasome 26S Subunit, Non-ATPase 14) within the context of LUAD is not well elucidated, especially in terms of its correlation with immune cell infiltration and the prognosis of patients.The objective of this research was to explore the expression levels of PSMD14 in LUAD and to evaluate its potential implications for tumor immunity and clinical outcomes. A multifaceted approach was adopted, which included the analysis of RNA sequencing (RNA-seq) data, assessment of immune cell infiltration, survival analysis, gene enrichment analysis, and integration of single-cell RNA-seq data to thoroughly evaluate the biological relevance of PSMD14. Furthermore, we examined the correlation between PSMD14 expression and clinical parameters.Immunohistochemistry techniques were employed to analyze PSMD14 expression in samples of invasive pulmonary adenocarcinoma.Results: Our study demonstrated that the expression of PSMD14 is markedly elevated in LUAD and exhibits a positive correlation with other members of the JAMM family, including EIF3H and PSMD7. Importantly, elevated levels of PSMD14 were linked to poor patient prognosis, indicating its potential utility as a biomarker. Moreover, KEGG pathway analysis revealed that PSMD14 is significantly associated with pathways related to the cell cycle and nicotine dependence, underscoring its vital function in modulating cell proliferation and metabolic activities. Furthermore, PSMD14 expression was found to be associated with the infiltration of immune cells, particularly influencing T helper and Th2 cell populations, and exhibited an inverse relationship with several immune checkpoint molecules, such as PD-1 and TIGIT. Insights from single-cell RNA sequencing identified that PSMD14-expressing immune cell types in LUAD include dendritic cell, monocytes, and tissue stem cells. These findings highlight the role of PSMD14 in the immune evasion strategies prevalent in LUAD. Additionally, a notable increase in PSMD14 protein levels was recorded in LUAD patients, with expression levels correlating with tumor size, lymph node involvement, and the TNM classification.In summary, our research underscores the crucial role of PSMD14 in LUAD, highlighting its promise as a potential target for therapy and a prognostic indicator. Furthermore, it opens up novel approaches for future therapeutic interventions.

Keywords: LUAD, PSMD14, Poor-prognosis predictor, Clinical stage, Single cell sequencing

Received: 14 Jan 2025; Accepted: 29 Apr 2025.

Copyright: © 2025 Zhang, Sun, Lai, Kong, Wang, Li, Wu and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Yichen Wu, Department of Pathology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Zhaochang Jiang, Department of Pathology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.